Phase I trial finds topical PXS-6302 generally well tolerated in established skin scars

Published Date: 13 Sep 2025

University of Western Australia's Burn Injury Research Unit with the Fiona Wood Foundation reports that topical pan-lysyl oxidase inhibition with PXS-6302 was generally well tolerated over three months and altered extracellular ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot